Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rifapentine - Sanofi

Next Previous
Drug Profile

Rifapentine - Sanofi

Alternative Names: DL 473; L 11473; M000473; MDL 473; Priftin; R 773

Latest Information Update: 15 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Centers for Disease Control and Prevention; Sanofi; sanofi-aventis
  • Class Antituberculars; Heterocyclic compounds; Piperazines; Rifamycins
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Tuberculosis
  • No development reported Mycobacterium avium complex infections

Most Recent Events

  • 10 Oct 2018 Sanofi plans a trial for Tuberculosis (Combination therapy) in Australia (ACTRN12618001672246p)
  • 07 Aug 2018 Launched for Tuberculosis in Russia (PO)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top